2012
DOI: 10.1186/1479-5876-10-48
|View full text |Cite
|
Sign up to set email alerts
|

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer

Abstract: A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly. Conventional cellular therapies, such as tumor infiltrating lymphocytes (TIL), are becoming more effective and more available. Gene therapy is becoming an important tool in adoptive cell therapy. Lymphocytes are being engineered to express high affinity T cell receptors (TCRs), chimeric antibody-T cell … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
34
0

Year Published

2012
2012
2019
2019

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 46 publications
(34 citation statements)
references
References 30 publications
0
34
0
Order By: Relevance
“…In recent decades various therapeutic approaches have been developed to utilize T and NK cells' ability to control tumor growth, such as vaccination and adoptive transfer of autologous ex vivo expanded or genetically modified T and NK cells [33][34][35][36][37][38][39][40][41][42]. Unfortunately, the therapeutic effects were limited.…”
Section: Introductionmentioning
confidence: 99%
“…In recent decades various therapeutic approaches have been developed to utilize T and NK cells' ability to control tumor growth, such as vaccination and adoptive transfer of autologous ex vivo expanded or genetically modified T and NK cells [33][34][35][36][37][38][39][40][41][42]. Unfortunately, the therapeutic effects were limited.…”
Section: Introductionmentioning
confidence: 99%
“…The successful transfer of genes encoding TCRab chains, which recognize a variety of virus-specific and tumor-associated antigens, into primary T cells has been demonstrated (Xue et al, 2005;Engels and Uckert, 2007;Heemskerk, 2010;Yin et al, 2011;Stroncek et al, 2012). In comparison with the transfer of both the TCRa and TCRb genes, which leads to the expression of the TCRab heterodimer in T-cells, the transfer of the TCRz gene into primary T cells appeared to be easier.…”
mentioning
confidence: 95%
“…Such cytotoxic T cells possess not only specific TCRs that recognize the tumor-associated antigens expressed on tumor cells, they also have active TCR signaling, which transduces the immune response and performs cytotoxic functions (Yin et al, 2011;Stroncek et al, 2012). The combined transfection of specific TCR and TCRz genes in T cells may be an ideal method to manufacture redirected T cells for immunotherapy.…”
mentioning
confidence: 99%
“…1,77 These include generating T-cell populations in vitro with specificity for antigens expressed on tumor cells for reinfusion, the development of tumor vaccines by expressing genes that enhance the immune response to injected tumor cells, and the creation of CARs on T cells in which a single-chain antibody with specificity for an antigen expressed on human tumor cells linked to internal domains that participate in cell activation. 77,78 Remission has been achieved in patients with B-lymphoid malignancies who received CAR-modified T cells (Table 2). [79][80][81] Fortunately, no evidence of T-cell transformation has been observed in these patients, although the period of observation is still rather short.…”
Section: Malignant Hematologic Disordersmentioning
confidence: 99%